Abstract: Objective To observe the effects of telbivudine combined with oxymatrine in patients with HBeAg positive chronic hepatitis B. Methods 65 cases of HBeAg positive CHB were randomly divided into two groups. In combined group（33 cases）,telbivudine was given 600 mg once a day and oxymatrine 0.6g/d. In telbivudine group（32 cases）,telbivudine was given alone. Clinical evaluation and laboratory detection were performed at the 12,26,52 weeks of the follow up period. Results At 12 weeks,undetectable rates of serum HBV DNA in combination group and telbivudine group were 45.4% and 31.3% respectively（P>0.05）;at 26 weeks,the rates were 72.7% and 46.9%,respectively（P<0.05）;at 52 weeks,the rates were 81.8% and 59.4%,respectively（P<0.05）. Seroconversion rates of HBeAg/HBeAb in combination group and telbivudine group were 12.1% and 6.3% respectively at 12 weeks（P>0.05）,But the seroconversion rates were 30.3% and 9.38% respectively at 26 weeks（P<0.05）; the seroconversion rates were 45.5% and 21.9% respectively at 52 weeks（P<0.05）. The normalization rates of ALT and TBIL in the two groups had no statistically significant difference（P>0.05）. There were no severe adverse reaction in both groups. Conclusion Telbivudine combined with Oxymatrine could enhance the effect of antivirus therapy for patients with chronic hepatitis B.

Key words: Chronic hepatitis B, Telbivudine, Oxymatrine